Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about t

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing

Kura Oncology maintains a “Strong Buy” rating, driven by KOMZIFTI's FDA approval and robust early co

The President and CEO acquired ~100,000 shares at $12.39 per share for a total transaction value of

Kura Oncology (KURA) gained attention today as CEO Troy Wilson bought another 100,000 shares for abo

Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 35.9% to $7.3 during Tuesday's

Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial res

Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform

Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let's fi

The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock.

US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other bi

Assenagon Asset Management S.A. lessened its stake in shares of Kura Oncology, Inc. (NASDAQ: KURA) b

Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% af

Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and raise

Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript

Kura Oncology NASDAQ: KURA reported second-quarter net product revenue of $9.1 million from KOMZIFTI

Kura Oncology (KURA) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Es

Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.77) per share which beat the analyst co

– KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approxi

– Publication details the discovery and preclinical characterization of ziftomenib, including its po

– Publication details the discovery and preclinical characterization of ziftomenib, including its po

SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a b

SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical

Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and main

Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib

Kura Oncology NASDAQ: KURA presented updated results from its Phase 1 FIT-001 trial evaluating darli

– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-

– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus ca

– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus ca

Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a rela

SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a b

Kura Oncology (NASDAQ:KURA) released first-quarter financial results and hosted an earnings call on

Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform

Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response r

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients

– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated an

Dow futures down 100 points. QuickLogic (QUIK) falls after reporting worse-than-expected Q1 results.

Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.83) per share which beat the analyst co

Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today

Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") and Kura Oncology, Inc. (NASDAQ:KURA, "

Kura Oncology says kidney cancer trial data shows 44% response rate and strong disease control; anal

Lake Street analyst Daniel Brims initiates coverage on Kura Oncology (NASDAQ:KURA) with a Buy rat

Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for t

Mizuho analyst Mara Goldstein maintains Kura Oncology (NASDAQ:KURA) with a Outperform and lowers

UBS analyst David Dai maintains Kura Oncology (NASDAQ:KURA) with a Buy and lowers the price targe

Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and lower